Lundbeck's schizophrenia treatment for teenagers receives FDA priority review status
Lundbeck and partner Otsuka have completed a supplemental drug application for the FDA to expand the use of schizophrenia drug Rexulti, one year earlier than expected.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
In December, Lundbeck and its partner Otsuka could potentially see the indication of their treatmeant of schizophrenia, Rexulti, expanded to include an important patient group in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New Lundbeck candidate to kick off R&D division
For subscribers
